Degree in Molecular Biology by the University of Barcelona, then moved to London where I did an MSc in Applied Biotechnology and Mol Biology and a PhD in Biochemistry in University College London. During this time I was sponsored by the Ministry of Defence and later by Zeneca Pharmaceuticals in the development of cancer therapy involving the use of mutated homologous proteins that will enzymatically cleaved a prodrug into a toxic drug at the site of the tumour.
In 1995, I went to Imperial College to lead a service facility in DNA sequencing, peptide synthesis and gene scan , research interests were in gene hunting for the Scholiosis gene among others.
In early 2002 I moved to the IAVI Core Laboratory within Imperial College where I manage the GCLP accredited clinical facility conducting the immunogenicity for Phase I/II HIV clinical trials and also support the wide network of IAVI field sites in Africa/India/Europe/US by providing training in immunological assays and QC and GCLP systems.
In 2012, I started in Imperial College as the Divisional Manager for Surgery within the Department of Surgery and Cancer. I am part of the management team to ensure the effective running of the Division of Surgery in relation to operational matters and the implementation of strategy and policy. As appropriate, I will deputise for the Departmental Manager.
It is a customer-focused service. I act as first point of contact for Research Services, Human Resources, Finance and, Estates/Facilities matters. Line manage administration/support staff including Finance Officer, Health and Safety Officer, an Academic Secretary and an Administrative Assistant.
et al., 2012, A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults, Plos One, Vol:7, ISSN:1932-6203
et al., 2011, Setting Up a Standardized Peripheral Blood Mononuclear Cells Processing Laboratory to Support Multi-center HIV/AIDS Vaccine and Intervention Trials, Labmedicine, Vol:42, ISSN:0007-5027, Pages:711-718
et al., 2011, In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers, Plos One, Vol:6, ISSN:1932-6203
et al., 2011, T-Cell Responses Induced by Immunization with Ad35-HIV-1 Vaccines Are Broad, Durable, Polyfunctional and Can Mediate Inhibition of HIV, Conference on AIDS Vaccine, MARY ANN LIEBERT INC, Pages:A20-A20, ISSN:0889-2229
et al., 2010, Preliminary results of safety and immunogenicity of Ad35-GRIN/ENV HIV Vaccine in HIV-uninfected subjects (IAVI B001), AIDS Vaccine 2010, MARY ANN LIEBERT INC, Pages:A16-A17, ISSN:0889-2229